In last trading session, Annovis Bio Inc (NYSE:ANVS) saw 0.34 million shares changing hands with its beta currently measuring 1.44. Company’s recent per share price level of $1.79 trading at $0.1 or 5.92% at ring of the bell on the day assigns it a market valuation of $34.88M. That closing price of ANVS’s stock is at a discount of -898.88% from its 52-week high price of $17.88 and is indicating a premium of 37.99% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.35 million shares which gives us an average trading volume of 387.82K if we extend that period to 3-months.
For Annovis Bio Inc (ANVS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.46 in the current quarter.
Annovis Bio Inc (NYSE:ANVS) trade information
Upright in the green during last session for gaining 5.92%, in the last five days ANVS remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $1.79 price level, adding 13.94% to its value on the day. Annovis Bio Inc’s shares saw a change of -64.41% in year-to-date performance and have moved 16.99% in past 5-day. Annovis Bio Inc (NYSE:ANVS) showed a performance of 42.06% in past 30-days. Number of shares sold short was 1.95 million shares which calculate 4.67 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 26 to the stock, which implies a rise of 93.12% to its current value. Analysts have been projecting 21 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -1073.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1073.18% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -73.95% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 27.81% while estimates for its earnings growth in next 5 years are of 19.39%.
Annovis Bio Inc (NYSE:ANVS)’s Major holders
Insiders are in possession of 14.28% of company’s total shares while institution are holding 16.02 percent of that, with stock having share float percentage of 18.70%. Investors also watch the number of corporate investors in a company very closely, which is 16.02% institutions for Annovis Bio Inc that are currently holding shares of the company. LMR PARTNERS LLP is the top institutional holder at ANVS for having 0.57 million shares of worth $3.3 million. And as of 2024-06-30, it was holding 5.0594 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.36 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.1956 of outstanding shares, having a total worth of $2.08 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 330.51 shares of worth $0.59 million or 1.70% of the total outstanding shares. The later fund manager was in possession of 129.74 shares on Dec 31, 2024 , making its stake of worth around $0.23 million in the company or a holder of 0.67% of company’s stock.
